LEDA Home Page HLSL Home PageLeda Search Results

Title: Patent Law, Antitrust Enforcement, and Public Access to Pharmaceuticals and Medical Technologies (2003 Third Year Paper)
Author(s): Laura J. Sigman
Subject & Subject keywords: Food and Drug Law "" "public access" "" "public welfare" "" "public health" "innovation" "patents"
Abstract:Patent and antitrust laws impact public access to pharmaceuticals and medical technologies. Two instances—one involving Roche’s new class of HIV/AIDS drugs, the other an antitrust action brought against Boston Scientific Corporation for violations of an anticompetitive agreement pertaining to cardiac treatment technology—illustrate the salient effects that medical products can have on public welfare. This paper provides a summary of patent laws, including provisions designed to advance the public interest, and explains the economic motivations underlying the patent regime. It also discusses the rationale behind antitrust laws and describes how courts account for public welfare when imposing damages for anticompetitive behavior. While it is difficult to assess the value of benefits and harm to the public, particularly where public health is concerned, legal regimes should aim to balance interests of producers and incentives for innovation with public needs for access to pharmaceuticals and medical devices.

PDF version (suitable for printing)
Sigman.pdf  (complete document)
HTML version (suitable for viewing with web browser)
Sigman.html  (complete document)
Rich Text Format version (suitable for use with word processor)
Sigman.rtf  (complete document)
ZIP'ped version (suitable for downloading)

Depositors authorize the Legal Information Institute to retain in perpetuity a digital copy of their scholarship and to provide, without charge, individual users of LEDA with the ability to view or print copies of a LEDA document for private, non-commercial use. Authors retain all other rights, including the rights of subsequent publication.